10-Q: Surrozen Reports Q1 2024 Results, Cites Progress in Clinical Programs and Recent Financing

Surrozen, Inc. announced its first quarter 2024 financial results, highlighting ongoing clinical trial progress and a recent private placement for additional funding.

Summary

• Surrozen, Inc., a clinical-stage biotechnology company, reported a net loss of $8.8 million for the first quarter of 2024, compared to a net loss of $14.3 million for the same period in 2023.
• The company's research and development expenses decreased to $5.2 million from $8.1 million year-over-year, primarily due to workforce reductions and the discontinuation of the SZN-1326 program.
• General and administrative expenses also decreased to $3.9 million from $5.3 million year-over-year, due to workforce reductions and lower consulting fees.
• As of March 31, 2024, Surrozen had cash and cash equivalents of $27.3 million and an accumulated deficit of $230.5 million.
• The company believes its existing cash, cash equivalents, and the $17.6 million gross proceeds from a private placement in April 2024 will be sufficient to fund operations for at least the next 12 months.
• Surrozen is actively initiating a Phase 1b clinical trial for SZN-043 in severe alcohol-associated hepatitis, with potential proof-of-concept data expected in the first half of 2025.
• The company anticipates the potential to nominate a lead Fzd-4 targeted Wnt agonist development candidate in 2024, which would trigger a $10.0 million milestone payment.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is progress in clinical programs and a recent financing, the company continues to incur significant losses and faces substantial risks. The sentiment is neutral to slightly negative due to the ongoing financial challenges and the inherent risks of drug development.

Positives

• The company has reduced its operating expenses, including research and development and general and administrative costs.
• The Phase 1a study for SZN-043 demonstrated acceptable safety and tolerability.
• Surrozen secured additional funding through a private placement, extending its operational runway.
• The company is progressing with its clinical programs, including the initiation of a Phase 1b trial for SZN-043.
• There is a potential for a $10 million milestone payment in 2024.

Negatives

• The company continues to incur significant net losses.
• There were treatment-related adverse events observed in the Phase 1a clinical trial for SZN-043, specifically asymptomatic transaminase elevations.
• The company has an accumulated deficit of $230.5 million.
• The company is dependent on raising additional capital to fund its operations.

Risks

• The company's ability to achieve profitability depends on obtaining regulatory approval and successfully commercializing product candidates.
• There is a risk that current or future product candidates may demonstrate undesirable side effects.
• The company relies on third parties for clinical trials and manufacturing, which may not perform satisfactorily.
• Clinical development activities could be delayed or adversely affected for various reasons.
• The company faces competition from other entities developing treatments for similar diseases.
• The company may not be able to maintain proper and effective internal controls over financial reporting.
• The company's business could be adversely affected by health epidemics, natural disasters, and other events.
• The company may depend on collaborations for the development and commercialization of product candidates, which may not be successful.
• The company may not be able to obtain or protect intellectual property rights related to its technology.
• The company may experience delays in clinical trials or may not be able to enroll a sufficient number of patients.
• The company may not be able to manufacture product candidates in sufficient quantities or of satisfactory quality.
• The company may not be able to enter into strategic transactions on acceptable terms.
• The company may not be able to attract and retain qualified key management, technical personnel and employees.

Future Outlook

The company expects to continue to incur losses for the foreseeable future and anticipates the need to raise additional capital to continue to execute its long-range business plan. Management believes that the existing cash, cash equivalents and the gross proceeds of approximately $17.6 million received in April 2024 from the closing of a private placement are sufficient for the company to continue operating activities for at least the next 12 months.

Management Comments

• Management believes that the existing cash, cash equivalents and the gross proceeds of approximately $17.6 million received in April 2024 from the closing of the private placement are sufficient for the company to continue operating activities for at least the next 12 months.
• The company expects to continue to incur losses for the foreseeable future and expects to incur increased expenses as it expands its pipeline and advances its product candidates through clinical development and regulatory submissions.

Industry Context

The announcement reflects the ongoing challenges and progress in the biotechnology sector, where companies like Surrozen are focused on developing novel therapies and navigating the complexities of clinical trials and regulatory approvals. The company's focus on the Wnt pathway and its application to various diseases aligns with broader industry trends in regenerative medicine and targeted therapies.

Comparison to Industry Standards

• The decrease in research and development expenses is consistent with other biotech companies that have undergone restructuring to focus on key programs.
• The company's cash runway of at least 12 months is typical for clinical-stage biotech companies, but the need for additional capital is a common challenge.
• The reported net loss is within the range of other companies at a similar stage of development, but the company's accumulated deficit is significant.
• The company's focus on the Wnt pathway is a novel approach, but it carries higher risks compared to more established therapeutic targets.
• The company's reliance on third-party manufacturers and CROs is standard practice in the industry, but it introduces risks related to quality and timelines.

Related Party Transactions

• In April 2024, the company entered into a sublease agreement with Nura Bio, Inc., where Tim Kutzkey, a member of the company's board of directors, serves as the chairman of the board of directors of Nura Bio.

Stakeholder Impact

• Shareholders may experience dilution from future equity issuances.
• Employees may be affected by potential future restructuring or workforce reductions.
• Customers (potential patients) may benefit from the development of new therapies.
• Suppliers and creditors may be impacted by the company's financial performance and ability to pay its obligations.

Next Steps

• The company will continue to advance its clinical programs, including the Phase 1b trial for SZN-043.
• The company anticipates nominating a lead Fzd-4 targeted Wnt agonist development candidate in 2024.
• The company will continue to evaluate and, if strategically attractive, seek to enter into collaborations.
• The company will continue to monitor and manage its cash burn rate.

Key Dates

Keywords

biotechnology, clinical trials, Wnt pathway, SZN-043, SZN-413, drug development, private placement, hepatitis, retinal diseases, licensing agreement